ATE226823T1 - Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten - Google Patents

Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten

Info

Publication number
ATE226823T1
ATE226823T1 AT99909110T AT99909110T ATE226823T1 AT E226823 T1 ATE226823 T1 AT E226823T1 AT 99909110 T AT99909110 T AT 99909110T AT 99909110 T AT99909110 T AT 99909110T AT E226823 T1 ATE226823 T1 AT E226823T1
Authority
AT
Austria
Prior art keywords
combination
alpha
nicotinergic
gaba
agonists
Prior art date
Application number
AT99909110T
Other languages
English (en)
Inventor
Gerard Raphael Dawson
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE226823T1 publication Critical patent/ATE226823T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99909110T 1998-03-16 1999-03-16 Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten ATE226823T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9805559.3A GB9805559D0 (en) 1998-03-16 1998-03-16 A combination of therapeutic agents
PCT/GB1999/000800 WO1999047142A1 (en) 1998-03-16 1999-03-16 Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist

Publications (1)

Publication Number Publication Date
ATE226823T1 true ATE226823T1 (de) 2002-11-15

Family

ID=10828630

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99909110T ATE226823T1 (de) 1998-03-16 1999-03-16 Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten

Country Status (9)

Country Link
EP (1) EP1061925B1 (de)
JP (1) JP2002506822A (de)
AT (1) ATE226823T1 (de)
AU (1) AU752013B2 (de)
CA (1) CA2324237A1 (de)
DE (1) DE69903716T2 (de)
ES (1) ES2185321T3 (de)
GB (1) GB9805559D0 (de)
WO (1) WO1999047142A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6723332B2 (en) 2000-05-26 2004-04-20 Neurogen Corporation Oxomidazopyridine-carboxamides
WO2002000623A2 (en) 2000-06-26 2002-01-03 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
GB9503601D0 (en) * 1995-02-23 1995-04-12 Merck Sharp & Dohme Method of treatment and method of manufacture of medicament
JP2000515851A (ja) * 1996-07-25 2000-11-28 メルク シヤープ エンド ドーム リミテツド ＧＡＢＡ▲下Ａα５▼レセプターサブタイプの逆アゴニストとしての置換のあるトリアゾロピリダジン誘導体

Also Published As

Publication number Publication date
AU2847799A (en) 1999-10-11
GB9805559D0 (en) 1998-05-13
EP1061925B1 (de) 2002-10-30
AU752013B2 (en) 2002-09-05
JP2002506822A (ja) 2002-03-05
DE69903716T2 (de) 2003-08-14
CA2324237A1 (en) 1999-09-23
WO1999047142A1 (en) 1999-09-23
EP1061925A1 (de) 2000-12-27
ES2185321T3 (es) 2003-04-16
DE69903716D1 (de) 2002-12-05

Similar Documents

Publication Publication Date Title
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
DE69528823D1 (en) Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
TR199801348T2 (xx) Heterosikl-kondanse morfinoid t�revleri(II).
DK0804196T3 (da) Anvendelse af serotoninantagonister (5HT 3) til behandling af fibromyalgia
DE69934241D1 (de) Agonistische antikörper gegen tie2
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
ATE291429T1 (de) Mittel gegen juckreiz
ATE465257T1 (de) Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
PT772603E (pt) Compostos substituidos de pirimidina e sua utilizacao
PT951282E (pt) Prevenção e tratamento de doenças esqueléticas com agonistas e2 de protaglandinas selectivos do subtipo de receptores ep2
DE59605568D1 (de) Benzonitrile als 5-HT Agonisten und Antagonisten
EA199900362A1 (ru) Новые соединения, полезные для использования в качестве нейрозащитных средств
BR9510499B1 (pt) antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados por il-5.
DK0615751T3 (da) Anvendelse af tachykininantagonister til behandling af emesis
BR9402890A (pt) Composição de lubrificante baseado em siloxano no segregador de hidrogênio.
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento
DE69903716D1 (de) Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties